Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant hematologic diseases, Blood, vol.91, pp.756-63, 1998. ,
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects, Blood, vol.97, pp.3390-400, 2001. ,
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versusleukemia without myeloablative therapy, Blood, vol.89, pp.4531-4537, 1997. ,
Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire, Exp Hematol, vol.36, pp.535-579, 2008. ,
Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigenmatched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation, Cancer, vol.119, pp.602-613, 2013. ,
Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age adapted strategy: longterm results of a prospective GOELAMS study, Blood, vol.119, pp.2943-2951, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00849702
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT), Eur J Haematol, vol.90, pp.177-86, 2013. ,
Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies, Haematologica, vol.99, pp.1762-1768, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01325488
The impact of graft-versus-host disease prophylaxis in reducedintensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Haematologica, vol.100, pp.683-689, 2015. ,
Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial, Cancer, vol.121, pp.562-571, 2015. ,
Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT, Bone Marrow Transplant, vol.49, pp.1170-1175, 2014. ,
Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Leuk Res, vol.39, pp.933-940, 2015. ,
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colonystimulating factor as salvage therapies for acute myeloid leukemia, Haematologica, vol.98, pp.114-118, 2013. ,
Clofarabine_ based chemotharapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience, Int J Hematol, vol.105, pp.769-776, 2017. ,
Randomized Phase www.oncotarget.com II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission, J Clin Oncol, vol.35, pp.1223-1230, 2017. ,
Clofarabine, a novel nucleoside analog is active in pediatric patients with advanced leukemia, Blood, vol.103, pp.784-789, 2004. ,
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia, J Clin Oncol, vol.24, pp.1917-1923, 2006. ,
Result from clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial, Haematologica, vol.99, pp.1486-91, 2014. ,
Clofarabine plus busulfan is an effective conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia: long-term study results, Biol Blood Marrow Transplant, vol.23, pp.285-292, 2017. ,
Clofarabine versus Fludarabine-based reduced-intensity conditioning regimen prior allogeneic transplantation in adult with AML/MDS, Cancer Med, vol.5, pp.3068-3076, 2016. ,
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, European LeukemiaNet. Blood, vol.115, pp.453-74, 2010. ,
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation, Blood, vol.125, pp.1333-1341, 2015. ,
Definition of GvHD-free, relapse-free survival for registrybased studies: an ALWP-EBMT analysis on patients with AML in remission, Bone Marrow Transplant, vol.51, pp.610-611, 2016. ,
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT), Leukemia, vol.19, pp.2304-2312, 2005. ,
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group, J Clin Oncol, vol.35, pp.185-193, 2017. ,
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission, Leuk Res, vol.63, pp.22-27, 2017. ,
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation, Leukemia, vol.29, pp.137-181, 2015. ,
Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia, Hematol Oncol, vol.36, pp.422-428, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01698460
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?, J Clin Oncol, vol.34, pp.329-365, 2016. ,
Minimal/ measurable residual disease in AML: a consensus document from the, European LeukemiaNet MRD Working Party. Blood, vol.131, pp.1275-1291, 2018. ,
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen, Blood, vol.102, pp.470-476, 2003. ,
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients www.oncotarget.com with myeloid malignancies undergoing allo-SCT, Bone Marrow Transplant, vol.47, pp.639-645, 2012. ,
Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases, Cancer, vol.119, pp.986-92, 2013. ,
The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation, Clin Lymphoma Myeloma Leuk, vol.14, pp.1-5, 2014. ,
Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia, Ann Hematol, vol.92, pp.1379-88, 2013. ,
Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and totalbody irradiation with post-transplant cyclophosphamide in non-remission AML, Int J Hematol, vol.108, pp.348-350, 2018. ,
Clofarabine-Based Reduced Intensity Conditioning Regimen with Post-Transplant Cyclophosphamide and Peripheral Stem Cell Graft in Adults with Myeloid Malignancies: Results of the Clo-Baltimore Regimen, Blood, vol.130, 1964. ,
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fmslike tyrosine kinase 3-mutated acute myeloid leukemia, Cancer, vol.123, pp.2867-2874, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01777827
Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome, Blood, vol.128, 1162. ,
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators, Stat Med, vol.18, pp.695-706, 1999. ,
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors, Transplantation, vol.18, pp.295-304, 1974. ,
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients, Am J Med, vol.69, pp.204-221, 1980. ,